A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Key Inclusion Criteria - Male or female participants 50 to 85 years of age - Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD - Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0 - Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging - Reliable study partner who can accompany the participant at study visits - If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment Key Exclusion Criteria - Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia. - History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study - Transient ischemic attacks (TIA) or stroke occurring within 12 months - Clinical evidence of liver or renal disease/injury - Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis - Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures - Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening - Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes - Taking any prohibited medications Other protocol-defined inclusion/exclusion criteria may apply Always talk to your doctor about whether this trial is right for you.